Cd29 pe clone mar4

Manufactured by BD

Sourced in Germany, Italy

CD29-PE (clone MAR4) is a flow cytometry reagent used for the detection and quantification of CD29, also known as integrin beta-1, on the surface of cells. It is conjugated with the fluorescent dye phycoerythrin (PE) for visualization during flow cytometric analysis.

Automatically generated - may contain errors

Lab products found in correlation

Spelling variants of this product

CD29-PE (51 citations)

2 protocols using cd29 pe clone mar4

Immunophenotypic Analysis of Stem Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Flow cytometric analysis of hematopoietic surface markers was analyzed on a FACS Canto II (BD Biosciences, Franklin Lakes, New Jersey, USA) with the following antibodies: CD3-PerCP-Cy5.5 (clone UCHT1), CD19-FITC (clone HIB19), CD31-PE (clone WM59), CD34-APC (clone 581), CD38-PE (clone HIT2), CD43-FITC (clone 1G10), CD14-PE (clone MOP9), CD66b-PE (clone G10F5) (all BD Bioscience), CD45-APC-Cy7 (clone 2D1), CD117-PE-Cy7 (clone 104D2), CD11c-PE-Cy7 (clone 3.9), HLA-DR-FITC (clone LN3), CD235a-Pacific Blue (clone 6A7M) (all eBioscience, San Diego, California, USA), CD33-APC (clone AC104.3E3; Miltenyi Biotec). EBs were dissociated with Accutase (Stemcell Technologies, Vancouver, British Columbia, Canada) for 10–15 min prior to staining with antibodies. Single cells were incubated with 1% human IgG solution (Privigen, CSL Behring, King of Prussia, Pennsylvania, USA) for 30 min at 4 °C to block unspecific binding.
Immunophenotypic analysis of MSCs and iMSCs was performed with CD14-APC (clone M5E2), CD29-PE (clone MAR4), CD31-PE (clone WM59), CD34-APC (clone 581), CD45-APC (clone HI30), CD73-PE (clone AD2), CD90-APC (clone 5E10) (all BD Biosciences), and CD105-FITC (clone MEM-226; ImmunoTools, Friesoythe, Germany). Data was analyzed using the FlowJo software (Tree Star, Ashland, Oregon, USA).

Cypris O., Frobel J., Rai S., Franzen J., Sontag S., Goetzke R., Szymanski de Toledo M.A., Zenke M, & Wagner W. (2019). Tracking of epigenetic changes during hematopoietic differentiation of induced pluripotent stem cells. Clinical Epigenetics, 11, 19.

+ Open protocol

+ Expand

Multicolor Flow Cytometry Analysis of MSC Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunophenotype analysis of mesenchymal, endothelial, human leucocyte antigen (HLA) and hematopoietic markers was performed by multicolor flow cytometry on c-kit + -derived cells. After detachment using a non-enzymatic method, cells were resuspended in PBS containing 0.1% BSA (Gibco, USA) and 2 mM EDTA (Gibco, USA) and incubated in the dark for 15 minutes with suitable combinations of the following monoclonal antibodies or isotype-matched control monoclonal antibodies: c-kit-APC (clone YB5.B8), CD34-FITC (clone 581), CD45-PE (clone HI30), CD29-PE (clone MAR4), CD31-FITC (clone WM59), CD90-FITC (clone 5E10), CD130-PE (clone AM64), HLA-DR-FITC (clone G46-6), CD73-PE (clone AD2), (BD Pharmingen, Italy), CD146-FITC (clone 128018), CD200-FITC (clone 325516), KDR-PE (clone 89106), (R&D Systems, USA), Lineage-biotin (MiltenyiBiotec, Italy), HLA-G-PE (clone MEM-G/9), (Exbio Praha, Czech Republic), CD144-Alexa700 (clone 16B1, eBioscience, UK). Samples were then washed with 1 mL of washing buffer and centrifuged for 10 minutes at 400 x g at 4°C to remove unbound antibodies. Cells were resuspended in 250 µL of washing buffer and analyzed.

Gambini E., Perrucci G.L., Bassetti B., Spaltro G., Campostrini G., Lionetti M.C., Pilozzi A., Martinelli F., Farruggia A., DiFrancesco D., Barbuti A, & Pompilio G. (2018). Preferential myofibroblast differentiation of cardiac mesenchymal progenitor cells in the presence of atrial fibrillation. Translational research : the journal of laboratory and clinical medicine, 192.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!